Rebalancing the fat content of the heart and muscles - Re-CHARM
Research type
Research Study
Full title
INTRAMYOCELLULAR LIPID COMPARTMENTS AFTER GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES
IRAS ID
341301
Contact name
Dana Dawson
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
4 years, 6 months, 31 days
Research summary
In this study we wish to compare the storage and turnover of saturated and unsaturated fat compartments in the heart and muscle in patients with type 2 diabetes.
There will be two study groups: one taking semaglutide only and the other taking semaglutide and following an exercise program.
We wish to establish:
1. If semaglutide results in a reduction of lean mass via a reduction in fat. This would be a different mechanism of weight loss than that obtained through exercise endurance training.
2. If the fat compartments in the heart and muscle are remodelled by semaglutide in a similar or different manner to that resulting from endurance exercise.
3. If exercise endurance training can be additive to semaglutide in achieving a superior cardio-metabolic health profile versus semaglutide alone.
REC name
North of Scotland Research Ethics Committee 1
REC reference
25/NS/0017
Date of REC Opinion
3 Mar 2025
REC opinion
Favourable Opinion